Ribociclib Succinate

Ribociclib Succinate
Product Description

Indicated in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy; or fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.

Read more Show less

OMGENE LIFE SCIENCES PRIVATE LIMITED

  • IN
  • 2020
    On CPHI since
  • 50 - 99
    Employees
Company types
Pharmaceutical company
View company profile
Categories
more categories Show less
Specifications
  • CAS Registry Number
    1211441-98-3
More specifications Fewer specifications

OMGENE LIFE SCIENCES PRIVATE LIMITED

  • IN
  • 2020
    On CPHI since
  • 50 - 99
    Employees
Company types
Pharmaceutical company
View company profile

More Products from OMGENE LIFE SCIENCES PRIVATE LIMITED (44)

  • Etelcalcetide

    Product Etelcalcetide

    Iindicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
  • Everolimus

    Product Everolimus

    Indicated for Prophylaxis of Organ Rejection in Kidney Transplantation and Prophylaxis of Organ Rejection in Liver Transplantation
  • Fulvestrant

    Product Fulvestrant

    Indicated for the treatment of Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression...
  • Ganirelix Acetate

    Product Ganirelix Acetate

    Indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. Close
  • Ixazomib Citrate

    Product Ixazomib Citrate

    Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
  • Lanreotide Acetate

    Product Lanreotide Acetate

    Indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.
  • Leuprolide Acetate

    Product Leuprolide Acetate

    Indicated in the palliative treatment of advanced prostatic cancer.
  • Linaclotide

    Product Linaclotide

    Indicated in adults for the treatment of irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC)
  • Liraglutide

    Product Liraglutide

    Indicated as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2   diabetes mellitus,  to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial   infarction, or non-fat...
  • Mebendazole (Micronized)

    Product Mebendazole (Micronized)

    Indicated for the treatment of patients two years of age and older with gastrointestinal infections caused by Ancylostoma duodenale (hookworm), Ascaris lumbricoides (roundworm), Enterobius vermicularis (pinworm), Necator americanus (hookworm), and Trichuris trichiura (whipworm).
  • Midodrine Hydrochloride

    Product Midodrine Hydrochloride

    Indicated for the treatment of symptomatic orthostatic hypotension (OH).
  • Midostaurin

    Product Midostaurin

    Indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by a FDA approved test
show all 44 other products

OMGENE LIFE SCIENCES PRIVATE LIMITED resources (1)